

---

# Enantioselective Synthesis of Oseltamivir Phosphate (Tamiflu) via the Iron-Catalyzed Stereoselective Olefin Diazidation


*Li, H.; Shen, S.; Zhu, C.; JACS 2018, xx, xx-xx*  
DOI: 10.1021/jacs.8b06900

---

*Leila Terrab  
Wipf Group  
Current Literature  
08/11/2018*

# Tamiflu®


- **Oseltamivir Phosphate (Tamiflu)**



- **1996: Developed by Gilead and Hoffman-La Roche**

- **Treats and prevents influenza A and influenza B**

- **Cells infected after enzymatic hydrolysis of terminal sialic acid from glycoconjugates**




**Sialic acids**


**Tamiflu mimics  
sialic acids**

# Previous Syntheses of Tamiflu®

## Roche:




## Fukuyama:



*J. Org. Chem.*, **1998**, 63 Vol. 63, 4545-4550

*Angew. Chem., Int. Ed.* **2007**, 46, 5734


# Proposed Functionalization




R = H, acyl, or aryl  
X, Y = H and leaving group

# Xu's Previous work on stereoselective diamination

## Diamination by benziodoxole activation:




## Diamination by peroxyester activation:



*Angew. Chem. Int. Ed.* **2016**, *55*, 534–538


*ACS Catal.* **2018**, *8*, 4473–4482

# Proposed Functionalization




underwent aromatization

**B**






more suitable substrate

**C**





R = H, acyl, or aryl  
X, Y = H and leaving group

# Diels Alder Synthesis of **C**



Kinetic Resolution using **Amano Lipase** from *Pseudomonas fluorescens*

# Azidation of (+)-25






# Mechanistic studies of azidation




19a is stable towards TMSN<sub>3</sub> without an iron catalyst



First C–N<sub>3</sub> bond forming step is reversible  
 Second C–N<sub>3</sub> bond forming step is rate-limiting

**Solution: increase [25] and decrease [19c]. Slow addition of 19c**

# Stereoselectivity of azide addition





**C<sub>4</sub> azide addition: dr >20:1**

**C<sub>3</sub> azide addition: dr = 7.4:1**

More reactive


dr not improved by iron catalysts used

# Stereoselectivity through Substrate Control




<sup>a</sup>Fe(OAc)<sub>2</sub> (5 mol %), **L1** (5 mol %), **19a** (2 equiv), CH<sub>2</sub>Cl<sub>2</sub>/MeCN (10:1), 0.8 M, 22 °C, TMSN<sub>3</sub> (5 equiv) added gradually within 8 h. <sup>b</sup>Fe(OAc)<sub>2</sub> (5 mol %), **L1** (5 mol %), **19a** (1.5 equiv), CH<sub>2</sub>Cl<sub>2</sub>/MeCN (10:1), 0.8 M, 22 °C, TMSN<sub>3</sub> (3.6 equiv) added gradually within 8 h. The reactions were subsequently quenched with saturated NaHCO<sub>3</sub> solution.



# Proposed Stereochemical Model



**R** group needs to be small to avoid  $\beta$  face transfer



# Synthesis of Tamiflu from the deamination intermediate



# Conclusion

